Streptococcus sanguinis (S. sanguinis) is one of the α -hemolytic streptococci that commonly reside in the human oral cavity. S. sanguinis, S. mitis, and S. oralis are categorized oral viridans. These bacteria, although less virulent (or non-pathogenic) in oral cavity, are the leading cause of infective endocarditis (Coykendall 1989; Ge et al. 2008; Kreth et al. 2008) . Pseudomonas aeruginosa (P. aeruginosa) is a non-capsulate and non-sporing Gramnegative bacillus that most commonly affects the lower respiratory system associated with nosocomial infections. On the other hand, P. aeruginosa is medically important pathogenic bacteria, which can cause chronic pulmonary disease and other infections including pneumonia, sepsis, and urinary tract infection, especially in immunocompromised individuals. Cystic fibrosis is characterized by emergence and persistence of chronic infection, mostly P. aeruginosa that produces a surface polysaccharide known as alginate (Kukavica-Ibruli and Levesque 2008; Campodonico et al. 2008; Winstaney and Fothergill 2009) . Antipseudomonal agents are available for controlling outbreak of P. aeruginosa. Low-dose macrolide therapy is commonly used to treat patients with chronic pulmonary infection, but there is some concerning the bacteria developing resistance to these drugs. Recently, treatment has become difficult due to nosocomial infections caused by multidrug-resistant P. aeruginosa (MDRP) (Basustaoglu et al. 1995; D'Agata 2004; Nouer et al. 2005; Rossoline and Mantengoli 2005; Bonomo and Szabo 2006; Paterson 2006; Hachem et al. 2007) .
MDRP strains cause nosocomial infections with an increasing ratio in recent years, which have become important clinical problem; thus, the development of a novel therapeutic drug is expected. We report here the bactericidal activity in filtrated supernatant of S. sanguinis (NNSSH strain, isolated from our Department of Clinical Medicine) against multidrug-resistant, mucoid and non-mucoid types of P. aeruginosa.
Materials and Methods

Bacteria
A non-pathogenic strain of S. sanguinis isolated from a patient's sputum was used in this study. It is α -hemolytic, Grampositive and resistant to optochin. The strain was identified using bacto-labo streptogram® according to the manufacturer's instructions (Wako, Osaka, Japan) . In this experiment, we used a strain of S. sanguinis named 'NNSSH' that exhibited the strongest bactericidal function. NNSSH strain was isolated at our department from a patient. Moreover, variations in bactericidal effect were observed among S. sanguinis strains. Twenty strains of P. aeruginosa isolated from the sputa of 20 patients with pulmonary diseases, including 2 MDRP strains and 5 mucoid type strains, were used in this study ( Table 1) .
The bactericidal effect in filtrated supernatant of NNSSH strain of S. sanguinis against bacteria other than P. aeruginosa was also evaluated. Other bacteria strains used were 9 species: 10 strains of Staphylococcus aureus (S. aureus), 10 strains of S. epidermides, 10 strains of Escherichia coli (E. coli), 10 strains of Klebsiella pneumoniae (K. pneumoniae), 10 strains of Enterobacter species (8 strains of Enterobacter cloacae; 1 strain of Enterobacter aerogenes; 1 strain of Enterobacter asburiae), 10 stains of Serratia species (one strain of Serratia liquefaciens; 3 strains of Serratia odorifera; 6 strains of Serratia morcescens), 5 strains of Citrobacter freundii, 9 strains of indole-positive Proteus species (5 strains of Providencia stuartii; 3 strains of Morganella morganii; 1 strain of Proteus vulgaris), and 10 strains of Acinetobacter baumannii (Table 2) .
Filtrated supernatant of S. sanguinis
Several colonies of NNSSH strain of S. sanguinis from 7% rabbit blood agar were inoculated in 3 ml of Todd-Hewitt broth (Difco, Detroit, MI, USA) and cultured overnight in static conditions. For negative control, Todd-Hewitt broth (3 ml) inoculated without bacteria was also cultured overnight in static conditions. In this study, aerobic condition was used for growth of S. sanguinis. They were subsequently centrifuged at 30,000 g for 30 min, and the supernatant was collected. This supernatant was filtrated with a commercially available filter (DISMIC ® -25cs, 0.20 µ m, Tokyo, Japan).
Treatment of P. aeruginosa
Each strain of P. aeruginosa was cultured overnight in 1 ml Muller-Hinton broth (Becton Dickinson Co., Sparks, MD, USA) at 35˚C and then adjusted to 10 5 cfu/ml using physiologic saline. This solution (0.1 ml) was mixed with filtrated supernatant of NNSSH strain and incubated at 35˚C under static conditions.
Determination of viable count of 20 strains of P. aeruginosa after treatment with filtrated supernatant of NNSSH strain a) Viable count: Viable counts of 20 strains of P. aeruginosa were determined by the quantitative culture method on the first, second, fourth, fifth, and sixth day after treatment with the filtrated supernatant of NNSSH strain. Gram-stain was performed for confirmation of bactericidal effect. b) Electron microscopic observation: Transmission electron microscopy (TEM) was used to observe any change that may have occurred on the structure of one smooth strain of P. aeruginosa. The sample was fixed for overnight at 4˚C in a solution containing 0.1 M cacodylate buffer pH 7.3 of 2% gluteraldehyde, then fixed with 1.5% osmium tetroxide, and embedded in epoxy resin. Ultrathin sections were stained with lead citrate and uranyl acetate. All specimens for TEM were examined with a JEM-1230 (JEOL Ltd., Tokyo, Japan) electron microscope operated at 80 kV and photographed.
Evaluation of bactericidal effect
Sterile 0.9% NaCl was used as a diluent for preparing dilutions of P. aeruginosa from 10 −1 , 10 −2 , 10 −3 , 10 −4 , 10 −5 , 10 −6 , and 10 −7 .
Bacterial growth in broth medium was observed usually turns the turbid medium. We evaluated the bactericidal effect in filtrated supernatant of NNSSH strain by using the minimum bactericidal concentration method (MBC). Thus, cultured broth medium was laid on BBL TSA II agar plate medium (Becton Dickinson Co., Sparks, MD, USA). The bactericidal effect was judged with or without bacterial colony on the agar plate medium. As a control, the bacteria were left untreated with filtrated supernatant of S. sanguinis (NNSSH).
Treatment with proteinase K or autoclave
The property of bactericidal component(s) was examined using proteinase K or autoclave treatment. Filtrated supernatant of NNSSH strain were treated with 0.1 ml of proteinase K (QIAGEN ® , QIAamp DNA mini kit, Tokyo, Japan) at 50˚C for 1 h to determine whether the bactericidal effect is medicated by a protein or not protein product. The enzyme was inactivated at 95˚C for 10 min. Likewise, the filtrated supernatant was autoclaved at 121˚C for 15 min to examine whether the bactericidal activity is heat-resistant or heat-labile.
Results
Effects of treatment with filtrated supernatant of NNSSH strain on the viable count of P. aeruginosa
All 20 strains of P. aeruginosa displayed viable count of 10 4 cfu/ml one day after treatment with filtrated supernatant of NNSSH strain. After 3 days, the viable count of 19 strains decreased to 10 3 to 10 2 cfu/ml, and the bacteria were observed at a small number. After 4 days, no viable bacteria were observed (Fig. 1) . The bacteria growth was not observed in 10 5 cfu/ml; on the other hand, broth turbid was observed in greater than 10 6 cfu/ml. In this study, 15 smooth strains and 5 mucoid strains were used. Of the 20 strains, one (5%), a mucoid strain of P. aeruginosa, was not affected by the treatment with the filtrated supernatant. Therefore, 19 strains of P. aeruginosa (15 smooth strains and 4 mucoid strains) were affected by bactericidal effect.
Morphological changes of cultured P. aeruginosa treated with filtrated supernatant of NNSSH strain
Gram-stain: After 3 days growth in the presence of filtrated supernatant of NNSSH strain, the characteristic morphological appearance was changed in P. aeruginosa. As shown in Fig. 2 , the shape of bacteria was change from rod to oval.
Transmission electron micrography: Control P. aeruginosa culture density was deep and uniform (Fig. 3A) . However, agglutination of bacterial somatic contents and fusional changes were seen in some areas of P. aeruginosa cultured in the presence of filtrated supernatant of NNSSH strain (Fig. 3B) . After 3 days, these changes progressed remarkably (Fig. 3C) .
Bactericidal effect on bacteria other than P. aeruginosa
Bactericidal effects were not observed with S. aureus, S. epidermidis, E. coli, K. pneumoniae, Enterobacter spp., Serratia spp., and Citrobacter freundii. The bactericidal effect was seen in 44% of indole-positive Proteus spp. and 60% of A. baumannii (Table 2) . 
Proteinase K and autoclave treatment of filtrated supernatant of NNSSH strain
In order to further characterize the active bactericidal component of the filtrated supernatant of NNSSH strain, the filtrated supernatant was treated with proteinase K or autoclaved. After proteinase K treatment or autoclave treatment, the bactericidal effect was detectable (Fig. 4. A and B) , which is similar to that of the untreated filtrated supernatant of NNSSH strain of S. sanguinis (see Fig. 1 ).
Discussion
The difficulty in effectively treating infections of highly resistant P. aeruginosa, especially MDRP, is a serious medical problem (Poole 2004) . In intractable infection for the mucoid type P. aeruginosa under the most of patients with chronic respiratory disease cases, low-dose macrolide therapy may provide good results (Keicho and Kudoh 2002; Equi et al. 2002; Kudoh and Keicho 2003) , but there is not enough effect of treatment. Colistin is the last choice for treatment of multidrug-resistant Gram-negative bacteria. Recently, colistin has been increasingly used in combination with one or more antibacterials for the treatment of MDRP patients. This combination therapy is used in order to improve the bactericidal activity for MDRP, despite the consequent increase in toxicity (Falagas and Kasiakou 2005; Li et al. 2006; Petrosillo et al. 2008 ). In a model of acute respiratory infection caused by P. aeruginosa, vaccination, a protein from a mucoid type P. aeruginosa was shown to effectively eliminate the bacteria from the lungs (Thomas et al. 2000) .
On the other hand, concerning bacteriocin, Dajani and co-workers (1976) reported that they had clinically isolated 22 strains of S. sanguinis, and the filtrated solution had shown 29% of bactericidal effects for P. aeruginosa. The growth factor was inhibited by bacteriocin-like (viridin) that was a kind of the protein, and the substance loses the bactericidal activity by heating at 60˚C. They described the growth repression factor was viridin. In our study, the fil- trated supernatant of S. sanguinis was observed bactericidal effect for P. aeruginosa, and our new-antipseudomonal substance was not destroyed by proteinase K and autoclave treatment. Therefore, the bactericidal component is completely different to Dajani's substance (Dajani et al. 1976 ). We are currently investigating the nature of the active bactericidal component present in filtrated supernatant of S. sanguinis. The activity was not altered after treatment with proteinase K and autoclave; thus, the bactericidal component is neither protein nor plasmid in nature. This bactericidal effect was observed on MDRP, both mucoid and non-mucoid types of bacteria, and the bactericidal rate indicated high as 95%, compared to 29% in the study of Dajani et al. (1976) . We showed the electron microscopic changes of P. aeruginosa after treating with the antipseudomonal component. And we investigated that bactericidal component also have the antiactivity for A. baumannii. The bactericidal component was also refined from the filtrated supernatant of cultured medium of oral viridans present in the normal flora of human oral cavity, which was observed unique as antipseudomonal component. The bactericidal effect attracted attention as pathogenic bacteria of the nosocomial infection. Recently, MDRP infection has become a serious problem clinically. Our urgent important task is to establish the novel alternative therapy for P. aeruginosa. Therefore, the bactericidal component will be developed as new treatment for P. aeruginosa. We believe that the active bactericidal component present in the filtrated supernatant of S. sanguinis offers a promising candidate for such therapies, and also we will investigate the way to make a new anti-pseudomonal drug in the near future.
